eliminated. This amount is considerably less than the balance. This is mainly the result of the complex elimination cumulative net weekly adsorption of P in the anuric kinetics of phosphate during dialysis. Removal of phosphate patient [5] , so there is a clear need to prevent intestinal is less than net dietary intake. Classical phosphate binders such absorption of P so as to achieve neutral P balance.
absorption of P so as to achieve neutral P balance.
as calcium carbonate, calcium acetate, and aluminum-based compounds are limited by side effects (hypercalcemia) and outright toxicity (aluminium). There have been numerous recent attempts to develop alternative phosphate binders, e.g.,
ELIMINATION KINETICS OF PHOSPHORUS
polyallylamine-hydrochloride (Renagel), lanthanum carbon-
DURING DIALYSIS
ate, and trivalent iron-containing compounds. The latter is
Although as a first approximation the elimination of based on old observations that iron salts may cause hyperphosurea follows first-order reaction consistent with uniform phatemia and rickets in experimental animals and in patients. This idea has recently been taken up again, and effective inhibidistribution in a single compartment, elimination kinetics tion of net intestinal phosphate uptake in non-uremic and ureof P are more complex. Hou et al. [4] as well as previous mic rats has been shown using simple iron salts (citrate, chloinvestigators [6, 7] found a rapid initial decrease of serum ride, ammonium citrate) and complex compounds (cross-linked P concentration during a dialysis session; as soon as the dextran and stabilized polynuclear iron hydroxide). In uremic rats, the latter compound reduces urinary phosphate excretion normal range of serum P concentration was reached, as an indicator of reduced intestinal phosphate uptake and has however, the serum P concentration tended to remain also been shown to be effective in subjects with preterminal constant independent of blood flow [7] . The major prorenal failure. So far, no side effects or short-term toxicity has portion of P was eliminated during the first hour. Conbeen observed. The compound appears promising and deserves versely, upon termination of hemodialysis, a rapid refurther evaluation.
bound occurred, and within 12 hr approximately 80% of predialysis serum P values were reached [6, 7] . The explanation is that P is sequestered in deep compartHyperphosphatemia continues to be a challenge for ments; the transfer rate constants from the intracellular the clinical nephrologist. Control of serum phosphate concentration is a central strategy in the treatment of secondinto the extracellular space are small, so that the rate of ary hyperparathyroidism, but it is also important in view P exit from intracellular space can no longer keep pace of recently recognized cardiovascular hazards of hyperwith the rate of removal through dialysis and becomes phosphatemia [1] . rate-limiting. That redistribution of P is indeed the botThe mass balance of phosphorus (P) is precarious in tleneck of P elimination has been nicely illustrated by the uremic patient on dialysis treatment. A normal Westrecent observations [8] showing that more frequent long ern diet contains approximately 800-1500 mg of P per dialysis sessions, i.e., 6 instead of 3 times per week, perday [2], of which 50-70% are absorbed in the intestine. mit elimination of substantial amounts of P, so that, It is still uncertain whether the net P intestinal absorption paradoxically, even addition of P to the dialysate is necesis less in the uremic patient compared to controls [3] , sary in some patients to prevent P depletion [9] . but if some intestinal malabsorption of P exists, it does Classical phosphate binders not have a major impact on prevention. According to Hou et al. [4] , during a 4-hour hemodialysis session using Very early on, this dilemma forced clinical nephrolo-1.0 m 2 cellulose acetate hollow fiber dialyzers, approxigists to use phosphate binders in order to sequester P in mately 33 mmol P are removed, so that with thrice the intestinal tract and to reduce entry of P into the extracellular fluid space. Historically, calcium carbonate and subsequently calcium acetate had been used most
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parathyroidism and a tendency for PTH (and in parallel linked iron dextran, i.e., iron (III)oxide-hydroxide-modified dextran [26] , as an oral phosphate binder in the rat. bone turnover) to be lower, the risk of hypercalcemia on oral calcium-containing phosphate binders has increased This was based on phosphate-binding studies in aqueous solutions and whole blood [27] , which had shown re- [10] . Although reducing the dialysate calcium concentrations diminishes the risk of hypercalcemia, Argiles et markable P binding efficacy. Binding was pH-dependent and maximal at pH 2-3, but when passage of the phosal. [11] showed that, in the long run, dialysate calcium concentrations below 6 mg/dl (1.5 mm) are not safe: they phate binders through the intestine was simulated in vitro by varying the pH over 6 hours, net binding capacity may cause stimulation of the parathyroid gland and loss of bone mineral, particularly if patients are noncompliant was still substantial and reduced only modestly compared to pH 2. Iron (III)oxide-hydroxide dextran beads with the intake of calcium-containing phosphate binders, so that the calcium balance becomes negative.
were exposed to chick duodenum to assess whether Fe was mobilized from the compound. Enzymatic iron liberAluminum-containing phosphate binders expose the uremic patient to the hazard of aluminum intoxication ation was very limited at best. In vivo studies with rats showed that, while plasma phosphate concentrations re- [12] . In an ideal world, aluminum-containing phosphate binders should be avoided completely, but, unfortunately, mained virtually unchanged when rats were fed with phosphate binder-containing food, the amount of P exone is often forced to use some when the use of calciumcontaining P binders leads to hypercalcemia [10] .
creted in the urine was lowered by a factor of 15. It was concluded that 1 g of this P binder will bind approxiNovel phosphate binders mately 0.65 mm of P. If one extrapolates to a 70 kg human being, approximately 15 g/day of the binder would be The dilemma of side effects (hypercalcemia with calcium-containing P binders) or toxicity (aluminum-connecessary. No animal died in the study by Spengler et al. [25] , animals grew and toxicity studies, including nectaining P binders) led to efforts to develop alternative P binders. One compound, polyallylamine-hydrochloride ropsy after 8 weeks of exposure, failed to reveal any evidence of subacute toxicity. Using an organic ferric (Renagel) has been intensively investigated in experimental and clinical [13] [14] [15] studies. This class of comcompound, Hsu et al. [28] , possibly unaware of this preceding study, fed ferric ammonium citrate and ferric pounds was originally developed to lower plasma lipids, and this effect is still seen with Renagel as well. Polyalchloride to normal and azotemic rats. They were on a 1.02% P diet to which the ferric salts had been added. lylamine-hydrochloride was shown to lower predialytic plasma P concentrations from 2.93 mm to 2.13 mm in a Urinary P excretion was consistently lowered. Since intake was unchanged, obviously net intestinal absorption short-term study, and similar effectiveness was also noted in long-term studies at a maximum daily dose of 5.5 g.
had been lowered. The authors calculated that the binding capacity was 88-181 mg of P per g of elemental iron. It is apparently somewhat difficult to lower P levels, as desired, in the mid-normal range, at least when this P Two recent observations point to the potential usefulness of these compounds in humans. We [29] exambinder is used as monotherapy.
Another approach is the development of lanthanumined 13 patients with stable preterminal renal failure (median serum creatinine 5.4 mg/dl). The patients were based compounds. Lanthanum-chloride-hydrate was studied in animal experiments [16] , and little tissue uptake hyperphosphatemic (median fasting plasma P 2.2 mm) on stable dietary P intake. After two weeks on no oral and toxicity was noted. A clinical study using lanthanum carbonate is currently underway, but the results are not P binders, 3 ϫ 2.5 g stabilized polynuclear iron hydroxyde was given with meals for 4 weeks-a deliberately subopavailable.
A third line of products concerns trivalent iron salts. timal dose. This dose caused a median decrease of fasting plasma P of 20%. Urinary P excretion was lowered even The available information on this interesting group of compounds will be discussed below. more, i.e., by 37%. Apart from a certain laxative action and black discoloration of feces, no side effects were Fe-III based phosphate binders noted in this short-term study. Figure 1 shows the individual changes in plasma phosphate and urinary P excretion Several anecdotal clinical observations [17, 18] document that ferric compounds bind dietary phosphate and rate. Of note, no significant changes in serum iron and serum ferritin were noted. In a preliminary study, Chang lower serum phosphate when given orally and even intravenously [19] . Iron salts have been shown to reduce bone et al.
[30] investigated 32 dialyzed uremic patients who were treated either with conventional phosphate binders ash in Guinea pigs [20] , to retard growth and induce phosphate depletion in rats [21, 22] , and to cause phosphate-(calcium carbonate and/or aluminum-containing compounds) or a non-ionic ferric polymaltose complex (Ferdeficiency rickets in chicken [23] as well as in swine [24] .
This line of observation lay dormant for a long time, rum chewable tablet, Hausmann Laboratories, Switzerland) containing 1.78 mmol elemental iron per tablet. but recently has been independently taken up by several groups of investigators. Spengler et al. [25] studied crossAfter wash-out of the P binders, plasma P was 2.64 and 2.53 mm in the two groups, which subsequently received the substance [29] . Further details are currently being assessed in a randomized prospective controlled study conventional P binders again or Ferrum tablets, respecin dialyzed patients. A potential advantage of these comtively. Ferrum was less effective than conventional P pounds is the favorable relation between cost and effecbinders. A mean decrease of 0.38 mm P was seen after tiveness. 8 weeks compared with 0.85 mm in controls, but at least Whether the combination of P binders and inhibitors proof of principle is provided by this preliminary obserof the intestinal Na,P-transporter [31] is a useful strategy vation. There was no significant change in ionized calwill require further studies. Available substances, e.g. cium, ferritin, serum iron, or iron saturation.
Niceritorol respect to absorption of iron (which may be a benefit in disguise in the age of erythropoietin treatment) and REFERENCES potential long-term side effects, e.g., binding of drugs, micronutrient binding. Nevertheless toxicity studies in 1. Amann K, Gross ML, London GM, Ritz E: Hyperphosphatemia-a silent killer of patients with renal failure? Nephrol Dial animals are very reassuring. The palatability of these com- and there were no complaints when patients received
